In this study we analyzed the individual value of baseline parameters to predict the outcome of high energy transurethral microwave thermotherapy in the treatment of patients with lower urinary tract symptoms and benign prostatic hyperplasia.
Introduction
The urological community is in an era of transition, embracing minimal invasive treatment modalities. The treatment of renal calculi, for example, has undergone dramatic changes. Improvements in imaging-technology combined with the advent of extra corporeal shockwave lithotripsy (ESWL) virtually have eliminated the need for open stone surgery. 1 Indeed, since the introduction of ESWL into clinical practice, this technique rapidly has become the treatment of choice for most renal calculi. In some circumstances, however, percutaneous procedures, ureteroscopy, or even open surgery are the preferred treatment options. 2 In other words one should keep in mind, when applying new technologies to the management of patients, multiple factors should be considered: each patient requires an unique solution.
At the moment a similar trend is observed in the management of male voiding dysfunction caused by benign prostatic hyperplasia (BPH). The number of surgically treated patients with lower urinary tract symptoms (LUTS) has decreased signi®cantly and alternative treatment options are numerous. 3, 4 Several interventional non-surgical modalities have emerged during the last decade and microwave technology is one of the most appealing options, applying thermal energy deep within the prostatic adenoma. 5 Recently a new generation TUMT (software high energy) has been introduced resulting in improvements of thermotherapy treatment outcome in general but at the cost of increased morbidity. 6 With the availability of different treatment protocols, one may ask what the position of this so-called high energy thermotherapy (HE-TUMT) treatment is. Since the advantage of the microwave technology lies in its power to tailor the treatment to the individual need we should indeed try to identify the ideal patient pro®le for this high energy treatment modality. During the International Consultation meeting on BPH in Monaco 1995, 7 a serious effort was made to describe outcome criteria in order to make treatment evaluation possible. Although we are aware of the fact that other outcome criteria are described (for example 30 or 50% improvement) we feel that at that meeting a consensus was reached for evaluation criteria. The following article describes the results of a multi variable analysis in a large cohort of patients treated with HE-TUMT, aiming at baseline parameters to independently predict treatment outcome.
Patients and Methods

Study population
Between October 1993 and July 1996, 247 men with lower urinary tract symptoms and BPH were treated using the high energy thermotherapy protocol (Prostasoft 2.5). All patients provided written informed consent before participation after verbal explanation and reading an explanatory lea¯et. Inclusion criteria were: males aged 45 y or older, with a total prostatic length of 25 mm or more and a prostate volume of 30 cc or more, voiding symptoms for longer than three months, a Madsen symptom score of eight or greater, a peak¯ow rate of 15 mlas or less with a minimum voided volume of 100 ml and post-voiding residual volume of 350 ml or less, and willingness and ability to comply with the study follow-up schedule and requirements. Patients with neurogenic disorders which may affect bladder function, prostatic carcinoma, surgical treatment of the prostate in the past, patients with possible microwave sensitive implants (pacemakers, hip prostheses), diabetic neuropathy, urinary retention requiring indwelling catheter, evidence of renal impairment, or an obstructed bladder neck by an enlarged median lobe of the prostate or patients who were on medication prescribed for the treatment of the prostate or bladder, were excluded from the study.
Clinical parameters
A urethrocystoscopy was carried out to judge the patency of the (prostatic) urethra for the presence of strictures or an isolated obstructing prostatic middle lobe and to exclude intra vesical pathology. Follow-up visits were scheduled at 12, 26 and 52 weeks after treatment and at every visit patients were asked to ®ll out a MadsenIversen symptom score and a IPSS symptom score. Urodynamic investigation with pressure-¯ow (PQ) study analysis was performed at baseline and 26 weeks post treatment. To quantify the grade of bladder outlet obstruction, urodynamic investigation with PQ analysis was performed. Intra vesical and rectal pressures were recorded using 8 F catheters mounted with microtip-sensors (MTC, Dra È ger, Germany), and detrusor pressure was calculated as the difference between these. The digitally stored pressure and¯ow-data were analyzed by a program developed at our department (UICaBME Research Center, Department of Urology, Nijmegen, The Netherlands). The following parameters derived from the pressure-¯ow analysis were used: detrusor pressure at maximum¯ow (P det at Q max in cmH 2 O), maximum¯ow rate (PQ-Q max in mlas), the linPURR (obstruction grading according to Scha È fer) and the urethral resistance index (URA in cmH 2 O).
Prostate con®guration and prostate volume were assessed at screening, 12 weeks and 52 weeks followup, by performing transrectal ultrasound (TRUSP) with a 7.5 MHZ transrectal probe (Combison 330 Voluson, Kretz Technik, Austria), volume being calculated using the ellipsoid formula. In case of an abnormality on either DRE, PSA-level or TRUSP, ultrasound guided prostate biopsies were performed.
Treatment
All TUMT treatments were performed on ambulatory basis using the Prostatron (EDAP Technomed, Lyon, France) device and the software 2.5. The method of therapy has been described previously. 8 Treatment duration was 60 min with increasing thermal dose up to 70 W. To prevent thermal damage to urethral mucosa and rectal wall thermal sensors, urethrally and rectally positioned, give continuous feedback signals about the temperature reached. When the maximum allowed temperature is detected by one of these thermo sensors the program automatically interrupts the treatment until the temperature decreases to a preset value. Two hours prior to treatment 40 mg of morphine sulfate was administered orally. During treatment additional intravenous sedation was given in 60 (24%) of patients, when they experienced major discomfort during treatment, mostly expressed as an intense urge to void. Since from initial experience we learned that urinary retention occurred in nearly all patients, patients were instructed in the need for a transurethral catheterisation for at average two to three weeks. Therefore in most cases the ®rst visit was at two weeks post treatment.
Statistical methods
Differences in the subjective and objective parameters between the points of measurement were tested for statistical signi®cance using the test of Friedman with corresponding contrast-tests. In order to evaluate outcome we used the response evaluation criteria as stated at the 3rd International Consultation on Benign Prostatic Hyperplasia in Monaco. 7 In the response evaluation criteria patients are strati®ed as poor, intermediate and good responders using either the IPSS symptom scores or the maximum¯ow rate or linPURR. The Kruskall±Wallis test was used to test for statistical signi®cant differences in the baseline parameters between the response groups of each criterium at each point of measurement.
Since we aimed at identifying responders from nonresponders, so-called intermediate responders were merged with the good responders. Differences in the baseline parameters between non-responders and responders at 26 weeks after treatment were expressed as crude odds ratios with 95% CI, using univariate logistic regression.
Multi variable logistic regression with forward selection procedures were used to select the baseline variables that contribute independently to the risk of non-response at week 26. Because forward selection procedures do not identify the other important variables, the P-values for entry into the model were considered in order to ®nd close alternatives to the variables selected. Data were presented as adjusted odds ratios with 95% CI. of the ®nal model.
Results
At screening 247 patients with a mean age of 66.3 y (s.d; 8.2 y) were treated with a mean total energy level of 159 KJ (s.d; 40 KJ). All patients tolerated the TUMT treatment well. The mean catheterisation time was 16.8 d (s.d; 16.1 d). The evaluation period was set at 12 weeks as follow-up data on all patients (n 247) studied was then available. Two hundred and ®ve patients however could be followed for 1 y as not all patients ful®lled 52 weeks follow-up. During the follow-up 15 patients (6%) needed additional medically or surgically therapy. One patient underwent a bladder neck incision, one urethrotomy because of a stricture, nine transurethral resection of the prostate, two laser prostatectomy, one open prostatectomy and one additional medical (a-adrenoceptor antagonist) treatment (Table 1) . Eventually 16 patients dropped out for reasons other than failure such as travel expenses or death not related to therapy and illness.
Because baseline parameters were investigated in a predictive manner in this study, possible correlations between these variables were analyzed using the Spearman Rank correlation test. The symptom score-parameters did not signi®cantly correlate with uro¯owmetry (voided volume, maximum¯ow rate and residual urine) and urodynamic (URA, linPURR, P det at Q max ) parameters. Age had a reversed correlation with the Madsen and IPSS symptom score and a positive correlation with PSA-level and prostate volume. Uro¯owmetry baseline parameters showed a weak but signi®cant correlation with the urodynamic parameters. Table 2 shows the mean of the subjective and objective parameters at each point of measurement. Statistical signi®cant improvement (59%) was observed in the Madsen symptom score at 12 weeks stabilizing up to 52 weeks follow-up. The same trend was observed for the IPSS score. The signi®cant decrease in prostate volume persisted after 12 weeks follow-up. At 26 weeks the urodynamic parameters signi®cantly improved from baseline. The uro¯ow parameters showed a signi®cant improvement in voided volume at 26 weeks stabilizing up to 52 weeks, whereas the residual urine decreased signi®cantly at 12 weeks. The maximum¯ow rate improved signi®cantly (62%) at 12 weeks. At 26 weeks, probably due to urodynamic investigation performed at that time, a little dip in improvement can be noticed. The patient distribution of the outcome (poor, intermediate and good response) at each point of measurement for the IPSS symptom score, for the maximum¯ow rate and for the urodynamic response, are presented in Table 3 . This shows that the number of poor responders on Q max and in linPURR is considerable at 26 weeks after treatment. Overall a higher age at baseline showed a poor response in the IPSS evaluation, independent of the response measurement date (12, 26 or 52 weeks post treatment), while the maximum flow response showed only a significantly higher age at baseline when measured at 26 weeks. In the urodynamic outcome analysis, age did not differ significantly in the responder groups. Regarding the total energy delivered the poor responders received significantly less energy compared to the good responders for IPSS at 12, 26 and 52 weeks. The energy delivered in poor responders for maximum flow was significantly lower than in good responders at 26 weeks which is also noticed for the poor responders for linPURR.
The urodynamic parameters showed a lower obstruction level at baseline in the poor response group for IPSS at 52 weeks. Evaluating the Q max group at 26 weeks, there appeared to be a lower linPURR at baseline in the poor responder group compared to the good responders. Finally the prostate volume at baseline appeared to be significantly lower in the poor responder group for lin-PURR while there was no significant difference found in the IPSS and Q max responder groups.
In order to identify the poor responders in each of the three evaluation criteria using baseline parameters, we focused on the 26 weeks follow-up. Figure 1 presents the odds ratio's and 95% con®dence intervals (CI) for poor response of each evaluation criteria of all baseline parameters sorted by magnitude for each response evaluation criterion. The horizontal reference line indicates an odds ratio equals one. For instance, in Figure 1A , the odds ratio for age at baseline is 1.034, this indicates that the relative chance for a poor response in IPSS at 26 weeks increases with 3.4% every year the patient is older at baseline which is, according to the 95% CI (0.99±1.08), not signi®cant. Delivering 1 KJ less energy to a patient however signi®-cantly increases the chance for poor response in IPSS with 2% (odds ratio 0.98, 95% CI 0.97±0.99)
In Figure 1A the total amount of energy delivered, the prostate volume, the PSA-level, the total Madsen score and the IPSS score are presented as being predicting baseline variables for a poor response in IPSS at 26 weeks follow-up. Figure 1B shows baseline parameters predictive for poor response in maximum¯ow at 26 weeks follow-up; linPURR, TUMT-energy, P det at Q max and maximum¯ow. Finally Figure 1C presents the P det at Q max , the maximum¯ow during urodynamic studies, the total amount of energy delivered, the prostate volume, the voided volume, the URA, the PSA-level and linPURR as predicting baseline variables for a poor response in linPURR at 26 weeks.
A forward selection procedure was performed with these baseline parameters to identify those baseline parameters that independently predict poor response. Table 5 shows the adjusted odds ratio's for poor response. Increasing age of patients, small prostates at baseline and a low total amount of energy delivered to the prostate were independently predictive factors for poor response in IPSS at 26 weeks. Using these variables, the IPSS and Madsen did not improve this model signi®cantly. When regarding the maximum¯ow rate as response at 26 weeks, the total energy applied and a low linPURR at baseline is predictive for a poor response. Using these variables, uro¯owmetry variables did not improve this model. The next best alternative for linPURR when performing the selection procedure appeared to be P det at Q max . When considering the linPURR at 26 weeks as outcome criteria a small prostate and a low total energy applied, are independently predictive baseline parameters for a poor response. Alternatives for prostate size in the selection appeared to be URA, P det at Q max , linPURR and maximum ow during urodynamic investigation.
Discussion
The treatment of lower urinary tract symptoms due to benign prostatic obstruction has more and more become a multi-modality therapy. At the moment the major medical treatment options are either alpha-blocker therapy or 5-alpha reductase inhibitor therapy. Treatment outcome for these therapies differ not only because of different mechanisms of action but also because the clinical trials use different inclusion criteria. Recently this resulted in an attempt to individualize the medical treatment in BPH, stratifying patients by their baseline prostate volume assessed by either transrectal ultrasound or MRI. The PROSPECT Study 9 with ®nasteride (5a-reductase inhibitor) treatment showed a signi®cant reduction in symptoms and improvement in maximum¯ow over baseline. With a maximum¯ow increase of 1.4 mlas and a decrease of symptom scores with 2.1 points further studies were advocated to determine if preselecting patients would improve the response rate and whether ®nasteride therapy would reduce the need for other (invasive) therapies. The meta-analysis by Boyle et al 10 suggested a better outcome when using ®nasteride in patients with larger prostates ( b 40 cc). With the arsenal of treatment modalities and in view of the different etiologies causing symptomatic BPH', this kind of case selection will become more and more important.
Transurethral microwave thermotherapy has been shown to be an effective, 1 h, without anaesthesia, outpatient treatment modality in patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Clinical studies of TUMT using the Prostatron with the high energy software 2.5, not only revealed a signi®cant subjective improvement, but also showed a signi®cant objective improvement in the same range as transurethral resection of the prostate.
6,11±13 Despite these good results, in a homogeneous population of patients there appeared to be a subgroup who responded better to treatment. Adaptation of vascularisation during the application of heat and inter individual variations in tissue composition of the prostate were considered to play an important role. 14, 15 To provide selection criteria for the lower energy protocol using the Prostasoft 2.0 de Wildt et al 16 analyzed the patient pro®le at baseline in a group responders and non-responders to this treatment. No clinical parameters could be identi®ed to predict clinical outcome or to preselect the ideal candidates for this treatment modality. When evaluating the results of the higher energy protocol version, it seemed that the best responders were patients with moderate to severe outow obstruction and patients with larger prostates. 6, 11, 12 These results were obtained by stratifying patients in preselected cohorts without knowledge of the contribution of each individual baseline-parameter to therapy-outcome.
Although the current analysis is performed for the prediction of a poor response, it con®rms the predictive values of both prostate volume and bladder outlet obstruction. However, depending on which evaluation criterion one selects, both parameters have different predictive values. Therefore a proper selection should be based on the use of a combination of baseline parameters (Table 5) .
In this analysis, the total amount of energy delivered by the Prostraton 2.5 software device, persisted in being of predictive value for outcome either in IPSS symptom score improvement, maximum¯ow improvement or urodynamically measured desobstruction. Urodynamic baseline parameters predicted outcome for maximum ow and IPSS at 26 weeks and 52 weeks, suggesting that these are more important in the prediction of durability of the symptomatic response to treatment. In an earlier study of d'Ancona et al 17 the same suggestion for durability was made.
Furthermore we found older patients to have less chance of a favorable outcome in symptom scores than the younger patients. The total amount of energy applied is of course not a baseline parameter, but directly post treatment it can be useful to be informed about the chances of a good or poor response. Being an operator independent procedure, the total amount of energy during high energy transurethral microwave thermotherapy varies markedly between patients due to the automatic urethral and rectal feedback mechanisms. The higher the amount of energy, the better the outcome, suggesting that other`baseline'-factors such as vascularisation and tissue composition of the prostate may be very important. Moreover it con®rms the thermoablative mechanism of the high energy transurethral thermotherapy.
Earlier studies 18, 19 already suggested the predictive value of urodynamic studies with pressure¯ow analysis and this study also con®rms the importance of this investigation when predicting outcome. Especially in predicting a poor response in the maximum¯ow parameter the pressure¯ow ®ndings are very useful.
Finally after thorough investigation four baseline parameters remained highly predicting for poor responses in the different evaluation categories. These variables have Ð not selected in the stepwise procedure CI Con®dence Interval. Example: The probability of poor response of IPSS at 26 weeks increases by 5.8% by every year of increasing age (which implies an increase of 76% by every 10 y).
different predictive values depending on the response evaluation criteria used. To re®ne this case selection, further strati®cation of these parameters must be performed to identify the`deal' response pro®le for high energy transurethral thermotherapy in the treatment of BPH.
Conclusion
High energy transurethral microwave thermotherapy in patients with lower urinary tract symptoms due to BPH, results in a signi®cant subjective and objective improvement. A high age, small prostates and a mild to moderate obstruction classi®cation according to the pressure¯ow analysis at baseline, were identi®ed as predicting baseline parameters for a poor response. The total amount of energy applied during treatment is not a baseline parameter but also has a highly predictive value for outcome. A perfect patient pro®le to predict treatment outcome is yet to be assessed. Other factors are most likely to be very important, such as vascularisation and tissue composition of the prostate.
